Here is Matt Lowdon‘s weekly deal update that covers news from the medical devices and biotech sectors. Headlines include news on Boston Scientific, AI drug discovery, neurotech and more. Congratulations to all involved.
🔔 Boston Scientific to snap up thrombectomy specialist Penumbra, Inc. in deal valued at $14.5B
🔔Eli Lilly and Company and NVIDIA, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon with biology through artificial-intelligence-powered drug development.
🔔Thermo Fisher Scientific teams up with Nvidia, TetraScience for next-gen AI workflow projects
🔔Italy’s Alfasigma pens €125M deal for injectable form of German biotech Innovative Molecules’s HSV treatment.
🔔Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs
🔔Caldera Therapeutics has burst onto the scene with $112.5 million in combined series A cash the Massachusetts biotech will use to fund development of an inflammatory bowel disease (IBD) drug licensed from China.
🔔Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro Pharmaceuticals.
🔔FineHeart has raised €83m ($96.6m) in public and private financing towards advancing the development of its implantable cardiac output accelerator for advanced heart failure treatment.